Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 19.19M 16.44M 15.41M 14.07M 26.56M 1.83B 26.82M 70.75M 923M 72.05M 70.48M 3.06B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 41.76M 35.79M 33.53M 30.63M 57.81M 3.98B 58.38M 154M 2.01B 157M 153M 6.65B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

28/06/25	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/06/24	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03/11/23	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23/10/23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
20/10/23	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
20/10/23	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
20/10/23	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
16/10/23	Irras Obtains Extension for SEK20 Million Loan	MT
16/10/23	Irras extends SEK 20 million short-term loan	FW
02/10/23	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
19/09/23	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
22/05/23	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
22/05/23	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
20/02/23	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

20/10/23	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
20/10/23	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
20/10/23	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
17/10/23	IRRAS publishes prospectus	AQ
16/10/23	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	01/07/2021
Griffen Stapp DFI	Director of Finance/CFO	40	17/06/2021
Sten Gustafsson IRC	Investor Relations Contact	-	09/03/2021

IRRAS AB Stock OTC Markets

Stocks

IRRA.F

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB

Latest news : IRRAS AB

Analysts' recommendations: IRRAS AB

Press Releases: IRRAS AB

Quotes and Performance

Managers and Directors: IRRAS AB

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	01/06/2015
Marios Fotiadis CHM	Chairman	53	18/08/2020
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	01/09/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB	-15.36%	-27.68%	-	-	16.9M
STRYKER CORPORATION	+0.85%	-0.24%	-15.42%	+18.87%	127B
SMITH & NEPHEW PLC	-1.29%	-3.83%	-22.78%	+0.85%	12.25B
GLAUKOS CORPORATION	-2.29%	-1.50%	+98.13%	+145.52%	10.69B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+2.13%	-4.21%	-51.63%	-68.92%	4.19B
DOUBLE MEDICAL TECHNOLOGY INC.	+0.57%	+4.02%	-22.01%	+58.76%	2.78B
INSPIRE MEDICAL SYSTEMS, INC.	-0.65%	+6.43%	-34.28%	-71.67%	1.77B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.12%	-0.84%	-23.32%	-12.99%	1.64B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+0.47%	-3.59%	-36.96%	-38.68%	1.57B
Average	-1.61%	+0.45%	-13.53%	+3.97%	20.21B
Weighted average by Cap.	+0.49%	-0.46%	-10.02%	+22.42%

	2023	2024
Net sales	42.88M 4.53M 3.88M 3.64M 3.32M 6.27M 432M 6.33M 16.69M 218M 17M 16.63M 721M	57.98M 6.12M 5.25M 4.92M 4.49M 8.47M 584M 8.56M 22.57M 294M 22.99M 22.49M 975M
Net income	-209M -22.05M -18.9M -17.71M -16.18M -30.53M -2.1B -30.83M -81.31M -1.06B -82.81M -81.01M -3.51B	-95.98M -10.13M -8.68M -8.14M -7.43M -14.03M -966M -14.17M -37.37M -487M -38.05M -37.22M -1.61B
Net Debt	43.85M 4.63M 3.97M 3.72M 3.4M 6.41M 441M 6.47M 17.07M 223M 17.38M 17M 737M	214M 22.57M 19.34M 18.12M 16.56M 31.24M 2.15B 31.55M 83.23M 1.09B 84.76M 82.91M 3.6B